# Frequently Asked Research Questions

> FAQ — British Colombia Peptides — Answers to common research questions about BPC-157, semaglutide, ipamorelin, NAD+ and GHK-Cu, drawn from cited studies and reviews.

**FAQ**

Short, cited answers. No dosing recommendations, no medical advice.

## What does BPC-157 do in the body?

In animal studies, BPC-157 has accelerated healing of gastric ulcers, torn tendons and damaged blood vessels, primarily by promoting angiogenesis — new blood-vessel growth — through the VEGFR2 receptor pathway [4][5][6]. Human evidence is limited to three small pilot studies, one of which found IV dosing well tolerated in two healthy adults with no measured harm to major organ systems [1][2].

## Does BPC-157 damage the liver?

The one published human safety pilot found no measurable change in liver (hepatic) biomarkers after intravenous BPC-157 in two healthy adults [1]. That is reassuring but far too small a sample to rule out liver effects generally; a 2025 review calls the overall human safety evidence too limited to draw firm conclusions and recommends treating BPC-157 as investigational [2].

## How does semaglutide work?

It activates GLP-1 receptors on pancreatic cells to boost glucose-dependent insulin release and suppress glucagon, slows gastric emptying, and acts on appetite-control circuits in the hypothalamus and brainstem to reduce food intake — the mechanism behind what patients often describe as quieter "food noise."

## How does semaglutide work for weight loss?

Its weight effect is centered in the brain: semaglutide activates hypothalamic and brainstem appetite circuits that promote fullness and suppress hunger signaling, reducing overall food intake and shifting food preference. In the SELECT trial, this translated into a 20% reduction in major cardiovascular events among people with obesity and existing heart disease, alongside weight loss [10].

## What is ipamorelin?

Ipamorelin is a synthetic five-amino-acid peptide that selectively activates the ghrelin receptor (GHS-R1a) on the pituitary gland, triggering a pulse of growth hormone release. It is not approved as a drug anywhere and is sold as a research chemical [16].

## What are the risks of ipamorelin?

Documented cautions are largely mechanism-based rather than drawn from long-term human trials, since none exist: theoretical concerns include stimulating pre-existing tumor growth via IGF-1, worsening insulin resistance, and a class-level cardiovascular signal from a 28-day rat study of a related ghrelin-receptor agonist that caused heart-muscle damage [14][17]. No equivalent long-term study of ipamorelin itself exists in any species.

## What is NAD supplement used for?

NAD+ and its precursors (NMN, NR) are marketed to raise the body's supply of a coenzyme central to energy metabolism and DNA repair, which declines with age. Human trials reliably raise blood NAD+ in a dose-dependent way [19][22], though a 2025 review concludes that translating this into proven clinical benefits still needs more research [18].

## What is the downside of taking NAD+?

Oral NAD+ itself is poorly absorbed, which is why precursors like NMN and NR are favored instead. IV/injectable NAD+ therapy rests on minimal controlled human evidence and can cause discomfort or nausea if infused too quickly; a compounded NAD+ injection has previously been subject to an FDA Class I recall over bacterial contamination. NMN's regulatory status as a supplement is also contested in the US.

## What does a GHK-Cu peptide do?

GHK-Cu is a copper-binding tripeptide that stimulates skin cells to produce more collagen, elastin and related structural proteins, while also cross-linking existing collagen fibers via its bound copper ion. Topical studies report it increased collagen production in 70% of treated women, versus 50% for vitamin C and 40% for retinoic acid [26].

## Is GHK-Cu peptide really anti-aging?

For skin specifically, controlled topical trials support meaningful effects on collagen production, wrinkle depth and skin laxity [26]. Broader systemic "anti-aging" claims rest mostly on gene-expression and rodent data rather than controlled human outcome trials, and a 2025 review is explicit that GHK-Cu's biggest practical limitation is that it penetrates skin poorly, which caps how much reaches living tissue from any topical product [23].

---

A literature desk on five research peptides, read against the Canadian regulatory backdrop — not a clinic, not a vendor, not a prescription.